You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Article metrics

Article menu

Download PDFPDF

Poster
IGCS20_1398
372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2020 to April 2024

AbstractFullPdf
Nov 20202907
Dec 20202307
Jan 20212604
Feb 2021401
Mar 202134011
Apr 202142010
May 2021105
Jun 2021402
Jul 2021105
Aug 2021006
Sep 2021003
Oct 202114019
Nov 202122018
Dec 20211002
Jan 2022801
Feb 20221401
Mar 2022805
Apr 20221202
May 2022608
Jun 20221004
Jul 20223001
Aug 20221305
Sep 2022607
Oct 2022402
Nov 20225002
Dec 20222802
Jan 20231803
Feb 20232101
Mar 20231801
Apr 2023800
May 2023800
Jun 2023802
Jul 20231504
Aug 20232604
Sep 2023202
Oct 2023801
Nov 20231001
Dec 20231700
Jan 20241401
Feb 20241602
Mar 20242202
Apr 20241402
Total6240166